title: Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
abstract: The chemokine receptor 4 (CXCR4) plays an important role in the growth, angiogenesis and metastasis of various cancers, including epithelial ovarian cancer (EOC). However, the correlation between CXCR4 and the clinical response of EOC patients to chemotherapy remains unknown. 124 EOC patients were recruited to assess the relationship between CXCR4 and the response to cisplatin-based chemotherapy. The results showed that patients with a higher CXCR4 expression had a significantly lower chemosensitivity, a poorer progression-free survival and a lower overall survival than those with lower CXCR4 expression. In addition, knockdown of CXCR4 by small interfering RNA suppressed cell proliferation and resulted in G1/S arrest, increased apoptosis and chemosensitivity in both cisplatin-sensitive A2780 cells and cisplatin-resistant cell A2780/cis in vitro. Our data suggest that CXCR4 is one of the key molecules in cisplatin-based chemotherapy for EOC patients and that CXCR4 inhibition is a potential strategy to address the chemoresistance of EOC.
authors.forename: Jia
authors.initials: J
authors.lastname: Li
authors.forename: Kuo
authors.initials: K
authors.lastname: Jiang
authors.forename: Xiuchun
authors.initials: X
authors.lastname: Qiu
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.forename: Qiang
authors.initials: Q
authors.lastname: Hao
authors.forename: Li
authors.initials: L
authors.lastname: Wei
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Gynecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, People's Republic of China cblxjh@fmmu.edu.cn.
authors.forename: BiLiang
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Gynecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, People's Republic of China xin_xy@163.com.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Xin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D059807:S Phase Cell Cycle Checkpoints / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C527276:CXCR4 protein, human; D034741:RNA, Small Interfering; D019718:Receptors, CXCR4; D002945:Cisplatin